(Q34293506)

1 August 2017

Development of Herceptin resistance in breast cancer cells (English)

1 reference

1 August 2017

0 references

1 reference

Timothy Kute

1

1 reference

1 August 2017

Christopher M Lack

2

1 reference

1 August 2017

Mark Willingham

3

1 reference

1 August 2017

Bimjhana Bishwokama

4

1 reference

1 August 2017

Holly Williams

5

1 reference

1 August 2017

Kathy Barrett

6

1 reference

1 August 2017

Tanita Mitchell

7

1 reference

1 August 2017

James P Vaughn

8

1 reference

1 August 2017

1 February 2004

1 reference

1 August 2017

1 reference

1 August 2017

57

1 reference

1 August 2017

86-93

1 reference

1 August 2017

2

1 reference

describes a project that uses

1 August 2017

BT-474 Clone 5

0 references

cites work

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

Trastuzumab/chemotherapy combinations in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

Trastuzumab-associated cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

Breast cancer banishes p27 from nucleus

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.A.10095

7 January 2021

Identifiers

DOI

10.1002/CYTO.A.10095

1 reference

1 August 2017

1 reference